Anti-desmoglein-1 levels as predictor of prednisolone tapering in pemphigus vulgaris patients treated with rituximab

Dermatol Ther. 2018 Nov;31(6):e12671. doi: 10.1111/dth.12671. Epub 2018 Sep 24.

Authors

Kamran Balighi¹, Roya-Sadaat Sakhi¹, Maryam Daneshpazhooh¹, HamidReza Mahmoudi¹, Amir Teimourpour¹, Soheil Tavakolpour¹

Affiliation

¹ Autoimmune Bullous Diseases Research Center, Tehran University of Medical Sciences, Tehran, Iran.

PMID: 30246907
DOI: 10.1111/dth.12671

No abstract available

Publication types

Letter

MeSH terms

Adult
Aged
Aged, 80 and over
Autoantibodies / blood*
Autoantibodies / immunology
Autoimmunity / drug effects*
Biomarkers / blood
Desmoglein 1 / immunology*
Drug Administration Schedule
Drug Monitoring / methods
Female
Glucocorticoids / administration & dosage*
Glucocorticoids / adverse effects
Humans
Immunologic Factors / administration & dosage*
Immunologic Factors / adverse effects
Male
Middle Aged
Pemphigus / blood
Pemphigus / diagnosis
Pemphigus / drug therapy*
Pemphigus / immunology
Predictive Value of Tests
Prednisolone / administration & dosage*
Prednisolone / adverse effects
Retrospective Studies
Rituximab / administration & dosage*
Rituximab / adverse effects
Treatment Outcome
Young Adult

Substances

Autoantibodies
Biomarkers
DSG1 protein, human
Desmoglein 1
Glucocorticoids
Immunologic Factors
Rituximab
Prednisolone